Evidence map›Paper›PMID 40442541›Full record

ArticleIn vitro cellular & developmental biology. Animal2025

miR-944 inhibits malignant progression of bladder cancer through ATIC/AKT/FOXO3 A axis mediated by SHMT1.

Zhiming Liu, Zhao Chen, Haibei Yang, Junning Liu, Maorong Cui, Weisheng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiming LiuDepartment of Urology, Qujing No.1 Hospital, No.1 Yuanlin Road, Qilin District, Qujing, 655000, Yunnan, China.
Zhao ChenDepartment of Urology, Qujing No.1 Hospital, No.1 Yuanlin Road, Qilin District, Qujing, 655000, Yunnan, China.
Haibei YangDepartment of Urology, Qujing No.1 Hospital, No.1 Yuanlin Road, Qilin District, Qujing, 655000, Yunnan, China.
Junning LiuDepartment of Urology, Qujing No.1 Hospital, No.1 Yuanlin Road, Qilin District, Qujing, 655000, Yunnan, China.
Maorong CuiDepartment of Urology, Qujing No.1 Hospital, No.1 Yuanlin Road, Qilin District, Qujing, 655000, Yunnan, China.
Weisheng WangDepartment of Urology, Qujing No.1 Hospital, No.1 Yuanlin Road, Qilin District, Qujing, 655000, Yunnan, China. wws13769874050@163.com.ORCID http://orcid.org/0009-0005-5271-6371

Funding

The Basic Research Program of Yunnan Province 202201AY070001-213
6 · The paper itself

Abstract

To investigate the role of miR-944 in the progression of bladder cancer (BC) and explore its potential as a therapeutic target. In this study, we collected 12 pairs of BC tissues and paracancerous tissues and subcutaneously injected T24 cells into BALB/c nude mice at 1 × 10

Indexed as

Disease ProgressionForkhead Box Protein O3Glycine HydroxymethyltransferaseMicroRNAsProto-Oncogene Proteins c-aktUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceForkhead Box Protein O3FOXO3 protein, humanGlycine HydroxymethyltransferaseMicroRNAsProto-Oncogene Proteins c-aktATIC/AKT/FOXO3 A signaling pathwayAutophagyBladder cancerMiR-944SHMT1

Identifiers

PMID40442541
PMCPMC12307474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.